Silencing Aurora-A with siRNA inhibits cell proliferation in human lung adenocarcinoma cells

Zhong,Ning; Shi,Shunbin; Wang,Hongzhen; Wu,Guangzhou; Wang,Yunliang; Ma,Qiang; Wang,Hongwei; Liu,Yuanhua; Wang,Jinzhi

doi:10.3892/ijo.2016.3605

Silencing Aurora-A with siRNA inhibits cell proliferation in human lung adenocarcinoma cells

Authors:
- Ning Zhong
- Shunbin Shi
- Hongzhen Wang
- Guangzhou Wu
- Yunliang Wang
- Qiang Ma
- Hongwei Wang
- Yuanhua Liu
- Jinzhi Wang
View Affiliations

Affiliations: Department of Thoracic Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu, P.R. China, Department of Thoracic Surgery, Affiliated Wujiang Hospital of Nantong Uinversity, Wujiang, Jiangsu, P.R. China, Department of Orthopaedics, the First People's Hospital of Kunshan City, Kunshan, Jiangsu, P.R. China, Department of Thoracic Surgery, Yancheng First People's Hospital Affiliated to Jiangsu University, Yancheng, Jiangsu, P.R. China, Department of Neurology, The 148 Central Hospital of PLA, Zibo City, Shangdong, P.R. China, State Key Laboratory of Organ Failure Research, Institute of Antibody Engineering, Southern Medical University, Guangzhou, Guangdong, P.R. China, Department of Medicine, The University of Chicago, Chicago, IL, USA, Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, P.R. China, Department of Cell Biology, School of Medicine, Soochow University, Suzhou, Jiangsu, P.R. China
Published online on: July 5, 2016 https://doi.org/10.3892/ijo.2016.3605
Pages: 1028-1038

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aurora kinase A (AURKA) is an oncogenic serine/threonine kinase, it plays important roles in tumorigenesis and chemoresistance. In this study, we investigated the expression of AURKA in lung adenocarcinoma tissues, the role of small interference RNA targeting AURKA on growth, cell cycle, and apoptosis of lung adenocarcinoma cell lines in vitro. The AURKA is highly expressed in lung adenocarcinoma tissues and human lung adenocarcinoma cell lines. Lentivirus-mediated short hairpin RNA (shRNA) was used to knock down AURKA expression in human lung adenocarcinoma cell lines H1299 and A549. The results indicated that depletion of AURKA could inhibit cell growth, cause cell cycle arrest and apoptosis. The potential mechanisms of AURKA inhibition induced cell cycle arrest and apoptosis are associated with downregulated RAF-1, CCND2, CCND3, CDK4, PAK4, EGFR and upregulated WEE1 expression. Furthermore, AURKA knockdown cooperated with vincristine (VCR) to repress A549 cell proliferation. Therefore, AURKA plays important roles in the proliferation of human lung adenocarcinoma cells, which suggests that AURKA could be a promising tool for lung adenocarcinoma therapy.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Chou HC and Chan HL: Effect of glutathione reductase knockdown in response to UVB-induced oxidative stress in human lung adenocarcinoma. Proteome Sci. 12:22014. View Article : Google Scholar : PubMed/NCBI
3	Pilotto S, Bria E, Peretti U, Massari F, Garassino M, Pelosi G and Tortora G: Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. J Thorac Oncol. 8:e105–e106. 2013. View Article : Google Scholar
4	Onn A, Tsuboi M and Thatcher N: Treatment of non-small-cell lung cancer: A perspective on the recent advances and the experience with gefitinib. Br J Cancer. 91(Suppl 2): S11–S17. 2004. View Article : Google Scholar : PubMed/NCBI
5	Fang W, Zhang J, Liang W, Huang Y, Yan Y, Wu X, Hu Z, Ma Y, Zhao H, Zhao Y, et al: Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis. 5:585–592. 2013.PubMed/NCBI
6	Shimada Y, Saji H, Nomura M, Matsubayashi J, Yoshida K, Kakihana M, Kajiwara N, Ohira T and Ikeda N: Cancer stem cell-related marker expression in lung adenocarcinoma and relevance of histologic subtypes based on IASLC/ATS/ERS classification. Onco Targets Ther. 6:1597–1604. 2013. View Article : Google Scholar : PubMed/NCBI
7	Dar AA, Goff LW, Majid S, Berlin J and El-Rifai W: Aurora kinase inhibitors - rising stars in cancer therapeutics? Mol Cancer Ther. 9:268–278. 2010. View Article : Google Scholar : PubMed/NCBI
8	Kallioniemi A, Kallioniemi OP, Piper J, Tanner M, Stokke T, Chen L, Smith HS, Pinkel D, Gray JW and Waldman FM: Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc Natl Acad Sci USA. 91:2156–2160. 1994. View Article : Google Scholar : PubMed/NCBI
9	Romain C, Paul P, Kim KW, Lee S, Qiao J and Chung DH: Targeting Aurora kinase-A downregulates cell proliferation and angiogenesis in neuroblastoma. J Pediatr Surg. 49:159–165. 2014. View Article : Google Scholar : PubMed/NCBI
10	Thrane S, Pedersen AM, Thomsen MB, Kirkegaard T, Rasmussen BB, Duun-Henriksen AK, Lænkholm AV, Bak M, Lykkesfeldt AE and Yde CW: A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in anti-estrogen-resistant breast cancer cells. Oncogene. 34:4199–4210. 2015. View Article : Google Scholar
11	Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494–498. 2001. View Article : Google Scholar : PubMed/NCBI
12	Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al; Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med. 14:822–827. 2008. View Article : Google Scholar : PubMed/NCBI
13	Zielske SP and Stevenson M: Importin 7 may be dispensable for human immunodeficiency virus type 1 and simian immunodeficiency virus infection of primary macrophages. J Virol. 79:11541–11546. 2005. View Article : Google Scholar : PubMed/NCBI
14	Jeng YM, Peng SY, Lin CY and Hsu HC: Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res. 10:2065–2071. 2004. View Article : Google Scholar : PubMed/NCBI
15	Sherr CJ: G1 phase progression: Cycling on cue. Cell. 79:551–555. 1994. View Article : Google Scholar : PubMed/NCBI
16	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
17	Dong Q, Meng P, Wang T, Qin W, Qin W, Wang F, Yuan J, Chen Z, Yang A and Wang H: MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One. 5:e101472010. View Article : Google Scholar : PubMed/NCBI
18	Mermelshtein A, Gerson A, Walfisch S, Delgado B, Shechter-Maor G, Delgado J, Fich A and Gheber L: Expression of D-type cyclins in colon cancer and in cell lines from colon carcinomas. Br J Cancer. 93:338–345. 2005. View Article : Google Scholar : PubMed/NCBI
19	Susaki E, Nakayama K and Nakayama KI: Cyclin D2 translocates p27 out of the nucleus and promotes its degradation at the G0–G1 transition. Mol Cell Biol. 27:4626–4640. 2007. View Article : Google Scholar : PubMed/NCBI
20	Hedberg Y, Roos G, Ljungberg B and Landberg G: Cyclin D3 protein content in human renal cell carcinoma in relation to cyclin D1 and clinico-pathological parameters. Acta Oncol. 41:175–181. 2002. View Article : Google Scholar : PubMed/NCBI
21	Ito Y, Takeda T, Wakasa K, Tsujimoto M and Matsuura N: Expression and possible role of cyclin D3 in human pancreatic adenocarcinoma. Anticancer Res. 21:1043–1048. 2001.PubMed/NCBI
22	Wong SC, Chan JK, Lee KC and Hsiao WL: Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast. J Pathol. 194:35–42. 2001. View Article : Google Scholar : PubMed/NCBI
23	Retzer-Lidl M, Schmid RM and Schneider G: Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of survivin. Int J Cancer. 121:66–75. 2007. View Article : Google Scholar : PubMed/NCBI
24	Karim BO, Rhee KJ, Liu G, Zheng D and Huso DL: Chemoprevention utility of silibinin and Cdk4 pathway inhibition in Apc(−/+) mice. BMC Cancer. 13:1572013. View Article : Google Scholar
25	Chan KC, Ting CM, Chan PS, Lo MC, Lo KW, Curry JE, Smyth T, Lee AW, Ng WT, Tsao GS, et al: A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Mol Cancer. 12:1282013. View Article : Google Scholar : PubMed/NCBI
26	Poomsawat S, Buajeeb W, Khovidhunkit SO and Punyasingh J: Alteration in the expression of cdk4 and cdk6 proteins in oral cancer and premalignant lesions. J Oral Pathol Med. 39:793–799. 2010. View Article : Google Scholar : PubMed/NCBI
27	Tang LH, Contractor T, Clausen R, Klimstra DS, Du YC, Allen PJ, Brennan MF, Levine AJ and Harris CR: Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6. Clin Cancer Res. 18:4612–4620. 2012. View Article : Google Scholar : PubMed/NCBI
28	Wu A, Wu B, Guo J, Luo W, Wu D, Yang H, Zhen Y, Yu X, Wang H, Zhou Y, et al: Elevated expression of CDK4 in lung cancer. J Transl Med. 9:382011. View Article : Google Scholar : PubMed/NCBI
29	Sørensen CS and Syljuåsen RG: Safeguarding genome integrity: The checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication. Nucleic Acids Res. 40:477–486. 2012. View Article : Google Scholar :
30	Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR, Jallal B and Smeal T: Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J Biol Chem. 277:550–558. 2002. View Article : Google Scholar
31	Siu MK, Chan HY, Kong DS, Wong ES, Wong OG, Ngan HY, Tam KF, Zhang H, Li Z, Chan QK, et al: p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci USA. 107:18622–18627. 2010. View Article : Google Scholar : PubMed/NCBI
32	Zhang HJ, Siu MK, Yeung MC, Jiang LL, Mak VC, Ngan HY, Wong OG, Zhang HQ and Cheung AN: Overexpressed PAK4 promotes proliferation, migration and invasion of choriocarcinoma. Carcinogenesis. 32:765–771. 2011.PubMed/NCBI
33	Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X, Lee HJ, Suh N, Yang CS and Minden A: The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res. 6:1215–1224. 2008. View Article : Google Scholar : PubMed/NCBI
34	Kimmelman AC, Hezel AF, Aguirre AJ, Zheng H, Paik JH, Ying H, Chu GC, Zhang JX, Sahin E, Yeo G, et al: Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci USA. 105:19372–19377. 2008. View Article : Google Scholar : PubMed/NCBI
35	Mitsudomi T and Yatabe Y: Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 277:301–308. 2010. View Article : Google Scholar
36	Cheng L, Zhang S, Alexander R, Yao Y, MacLennan GT, Pan CX, Huang J, Wang M, Montironi R and Lopez-Beltran A: The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol. 7:519–541. 2011. View Article : Google Scholar : PubMed/NCBI
37	Pao W and Chmielecki J: Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer. 10:760–774. 2010. View Article : Google Scholar : PubMed/NCBI
38	Yamamoto H, Toyooka S and Mitsudomi T: Impact of EGFR mutation analysis in non-small cell lung cancer. Lung Cancer. 63:315–321. 2009. View Article : Google Scholar
39	Inamura K, Ninomiya H, Ishikawa Y and Matsubara O: Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med. 134:66–72. 2010.PubMed/NCBI
40	Alejandro EU, Kalynyak TB, Taghizadeh F, Gwiazda KS, Rawstron EK, Jacob KJ and Johnson JD: Acute insulin signaling in pancreatic beta-cells is mediated by multiple Raf-1 dependent pathways. Endocrinology. 151:502–512. 2010. View Article : Google Scholar : PubMed/NCBI
41	Wang H, Gambosova K, Cooper ZA, Holloway MP, Kassai A, Izquierdo D, Cleveland K, Boney CM and Altura RA: EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic β-cells. BMC Mol Biol. 11:662010. View Article : Google Scholar
42	Yoon S and Seger R: The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions. Growth Factors. 24:21–44. 2006. View Article : Google Scholar : PubMed/NCBI
43	Magnussen GI, Holm R, Emilsen E, Rosnes AK, Slipicevic A and Flørenes VA: High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: Potential for targeted therapy. PLoS One. 7:e382542012. View Article : Google Scholar : PubMed/NCBI
44	Murrow LM, Garimella SV, Jones TL, Caplen NJ and Lipkowitz S: Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat. 122:347–357. 2010. View Article : Google Scholar
45	Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts D, Kaspers GJ, et al: In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell. 18:244–257. 2010. View Article : Google Scholar : PubMed/NCBI